65,437 trials
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) — 47.2; 44.9 Percentage of participants
Schizophrenia
Primary: Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs) — 72; 7; 13 participants
Cervical Cancer
Primary: Concordance of Pap Test Results Between Self- and Physician-collected Pap Tests — 8; 89; 2; 3 Participants
Obesity
Primary: Change in Body Weight — 9.3; 8.3 kg
Bipolar Disorder · Cardiovascular Disease
Primary: Systolic and Diastolic Blood Pressure (SBP, DBP) — 127.2; 130.4; 75.9; 78.5 mm/Hg — p=<.05
Age-related Macular Degeneration · Depression
Primary: Depression — 11; 18; 5; 11 participants — p=.067
Steatohepatitis
Primary: Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies — 18; 18; 20 participants — p=0.57
Multiple Myeloma
Primary: The Maximum Tolerated Dose (MTD) of Carfilzomib — 36 mg/m^2
Ischemic Stroke
Primary: A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days. — 681; 683 participants
Ovarian Neoplasms · Peritoneal Neoplasms
Primary: Maximum Tolerated Dose of Nintedanib Based on the Occurrence of DLTs During Treatment Course 1 — NA; 200 mg
Type 2 Diabetes
Primary: Change in Hemoglobin A1C Level From Baseline — 0.09; -0.11 percentage of change from baseline — p=<0.05
Hearing Loss
Primary: Ability to Understand Speech in Noise Background — 84; 78; 47 Percent correct of 100 presented words
Diagnostic and/or Interventional Radiology Procedures
Primary: Rate of Major Vascular Complications — 0.7 Percentage of Procedures
Epilepsy
Primary: Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Safety Follow-up Visit — 55 participants
Pancreatic Pseudocyst(s)
Primary: Safety - Freedom From Major Complications: Access Site-related Bleeding — 100 percentage of patients